What is MAVYRET?
MAVYRET is a prescription medication used to treat chronic hepatitis C virus (HCV) infection in adults. The medication is a combination of glecaprevir and pibrentasvir, two antiviral drugs that work by targeting multiple steps in the HCV life cycle.
MAVYRET is indicated for the treatment of all major genotypes (1-6) of HCV in patients with or without cirrhosis. The medication is taken orally once daily for eight to twelve weeks, depending on the severity of the infection and the patient's medical history.
Clinical trials have shown that MAVYRET is highly effective at curing HCV infection, with cure rates ranging from 92% to 100%. The medication is generally well-tolerated, with common side effects including headache, fatigue, and nausea.
Before taking MAVYRET, patients should inform their healthcare provider of any medical conditions or medications they are taking, as well as any history of HCV treatment or liver disease. Patients should also be monitored closely during treatment to ensure the medication is working effectively and to detect any potential side effects.
Overall, MAVYRET has revolutionized the treatment of chronic HCV infection, offering patients a highly effective and well-tolerated option for achieving cure. However, it is important for patients to work closely with their healthcare provider to ensure safe and effective treatment.
Frequently Asked Questions about mavyret
These polypeptides are effective targets for antiviral therapy of hepatitis C. Mavyret is a fixed dose combination of glecaprevir (glek a' pre vir) which is a potent HCV NS3/4 protease inhibitor and pibrentasvir (pi brent' as vir) an HCV NS5A inhibitor.
MAVYRET is a fixed-dose combination tablet containing glecaprevir and pibrentasvir for oral administration. Glecaprevir is a HCV NS3/4A PI, and pibrentasvir is a HCV NS5A inhibitor.
Mechanism of Action
Glecaprevir is an inhibitor of the HCV NS3/4A protease, which is necessary for the proteolytic cleavage of the HCV encoded polyprotein and for viral replication. Pibrentasvir is an inhibitor of HCV NS5A, which is essential for viral RNA replication and virion assembly.
Mavyret has an average rating of 8.4 out of 10 from a total of 403 reviews on Drugs.com. 80% of reviewers reported a positive experience, while 8% reported a negative experience.
AbbVie Inc. is the maker and marketer of MAVYRET® (glecaprevir/pibrentasvir).
MAVYRET is a pan-genotypic treatment approved for use in patients across all stages of CKD. Glecaprevir (GLE) was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (NASDAQ: ENTA) for HCV protease inhibitors and regimens that include protease inhibitors.
Glecaprevir/pibrentasvir (Mavyret) is a combination of a hepatitis C virus (HCV) NS3/4A protease inhibitor and an HCV NS5A inhibitor.
Mavyret is an antiviral prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus infection (HCV) in adults and children 3 years of age and older who meet certain requirements, as determined by a health care provider.
Based on clinical trials, 98% of people who take MAVIRET as directed can expect to be cured^ of their hepatitis C (hep C), meaning that the hep C virus has been cleared from the body. ^Cure means the hep C virus is not found in the blood 3 months after treatment ends.
In people who had or have advanced liver problems before starting treatment with MAVYRET, there is a rare risk of worsening liver problems, liver failure, and death. Your doctor will check you for signs and symptoms of worsening liver problems during treatment with MAVYRET.
The U.S. Food and Drug Administration today expanded the approval of Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ages 12 years and older or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection ...
Glecaprevir/pibrentasvir (G/P), sold under the brand names Mavyret and Maviret, is a fixed-dose combination medication used to treat hepatitis C.
On August 3, 2017, the US Food & Drug Administration (FDA) approved MAVYRET (glecaprevir and pibrentasvir) for treatment of patients with: Chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A).
